scholarly journals Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event

2020 ◽  
Vol 18 (11) ◽  
pp. 2861-2869
Author(s):  
Hanne Skille ◽  
Benedikte Paulsen ◽  
Kristian Hveem ◽  
Maiken E. Gabrielsen ◽  
Ben Brumpton ◽  
...  
Keyword(s):  
Thromboembolic Event ◽  
Venous Thromboembolic Event ◽  
Combined Effects ◽  
Venous Thromboembolic

Thrombosis and the Antiphospholipid Syndrome

Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 462-468 ◽  
Author(s):  
Thomas L. Ortel
Keyword(s):  
Risk Factors ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Thromboembolic Event ◽  
Randomized Clinical Trials ◽  
Venous Thromboembolic Event ◽  
Thromboembolic Events ◽  
Additional Risk ◽  
Initial Event ◽  
Venous Thromboembolic

Abstract The antiphospholipid syndrome is an antibody-mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events. Several studies have determined that the frequency of antiphospholipid syndrome in patients presenting with a venous thromboembolic event is between 4% and 14%. Because of the high risk for recurrent thromboembolism in these patients, current recommendations suggest a longer, potentially lifelong, course of antithrombotic therapy following an initial event. Although most authorities agree on an extended course of therapy, considerable controversy surrounds the optimal target therapeutic INR for patients with antiphospholipid syndrome. For an initial venous thromboembolic event, a target INR of 2.0 to 3.0 is supported by two prospective, randomized clinical trials. In contrast, relatively limited data exist for an initial arterial thromboembolic event in patients who have the antiphospholipid syndrome, and therapeutic recommendations range from aspirin to warfarin with a high target INR. Recurrent thromboembolic events can be extremely difficult to treat, and some patients may benefit from the addition of immunosuppressive therapies. Importantly, as many as 50% of the initial thromboembolic events sustained by patients with antiphospholipid antibodies occur in the setting of additional, coincident prothrombotic risk factors, indicating the importance of addressing any additional risk factors, such as hypercholesterolemia, in these patients. Prospective studies are needed to address the role of thromboprophylactic strategies in asymptomatic individuals with antiphospholipid antibodies in the absence of additional risk factors.

scholarly journals Association of the Risk of a Venous Thromboembolic Event in Emergency vs Elective General Surgery

JAMA Surgery ◽  
2020 ◽  
Vol 155 (6) ◽  
pp. 503 ◽  
Author(s):  
Samuel W. Ross ◽  
Kali M. Kuhlenschmidt ◽  
John C. Kubasiak ◽  
Lindsey E. Mossler ◽  
Luis R. Taveras ◽  
...  
Keyword(s):  
General Surgery ◽  
Thromboembolic Event ◽  
Venous Thromboembolic Event ◽  
Venous Thromboembolic

Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database

2016 ◽  
Vol 24 (1) ◽  
pp. 22-27 ◽  
Author(s):  
Chikako Matsumura ◽  
Yugo Chisaki ◽  
Satoko Sakimoto ◽  
Honoka Sakae ◽  
Yoshitaka Yano
Keyword(s):  
Risk Factors ◽  
Cancer Patients ◽  
Adverse Drug Event ◽  
Thromboembolic Event ◽  
Venous Thromboembolic Event ◽  
Drug Event ◽  
Thromboembolic Events ◽  
Event Report ◽  
Patients With Cancer ◽  
Venous Thromboembolic

Purpose We aimed to examine the risk factors, time of onset, incidence rates, and outcomes of thromboembolic events induced by bevacizumab in patients with cancer using the Japanese Adverse Drug Event Report (JADER) database of the Pharmaceuticals and Medical Devices Agency. Methods Adverse event data recorded in the JADER database between January 2004 and January 2015 were used. After screening the data using the generic drug name bevacizumab, patient data were classified into two groups by age and five groups by cancer type. The histories of disorders were also categorized. Arterial thromboembolic event and venous thromboembolic event were classified as “favorable” or “unfavorable” outcomes. Results In total, 6076 patients were reported to have developed adverse events during the sample period, of which 233 and 453 developed arterial thromboembolic event and venous thromboembolic event, respectively. Logistic analysis suggested that the presence of cancer was a significant risk factor for both arterial thromboembolic event and venous thromboembolic event. Age (≥70 years), histories of either hypertension or diabetes mellitus were also risk factors for arterial thromboembolic event. Median cumulative times of onset for arterial thromboembolic event and venous thromboembolic event were 60 and 80 days, respectively, and were not significantly different by the log-rank test. By the chi-square test, the rate of unfavorable outcomes was found to be higher after developing arterial thromboembolic event than after venous thromboembolic event. Conclusion Thromboembolism is a leading cause of mortality in patients with cancer. Patients should be monitored for the symptoms of thromboembolic events right from the initial stages of bevacizumab treatment.

Prevalence of Antiphospholipid Anitbodies in Idiopathic Venous Thromboembolism.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 529-529 ◽  
Author(s):  
Koushi Paramsothy ◽  
Philip S. Wells
Keyword(s):  
Venous Thromboembolism ◽  
Thromboembolic Event ◽  
Retrospective Chart Review ◽  
Venous Thromboembolic Event ◽  
Anticardiolipin Antibodies ◽  
Ottawa Hospital ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Time Of Presentation ◽  
Positive Results

Abstract The presence of antiphospholipid antibodies (APLA), which include lupus anticoagulant (LA) and anticardiolipin antibodies (ACA), increases the risk of venous thromboembolism (VTE). Although, the association demonstrated between LA and VTE is strong, that between ACA and VTE is weak with the exception of high titers. This suggestion has been that this may be related to the induction of ACA by acute illness. This may be the explanation for the widely varying frequency of ACA positivity in patients with acute VTE in the current medical literature. The prevalence of LA in patients with acute VTE is more consistent but the value of testing for ACA and LA at presentation of acute VTE remains unknown. We routinely test all idiopathic VTE patients at presentation for LA and ACA. It had been our impression that most positive results revert to normal with subsequent testing. We sough to test this hypothesis. The objective was to determine the prevalence of abnormal LA and ACA results and the frequency of subsequent normalization in patients presenting with a first idiopathic venous thromboembolic event. A retrospective chart review was conducted at the Thrombosis Unit at the Ottawa Hospital. 278 charts of unrelated, consecutive patients with idiopathic VTE were reviewed. 232 patients with single idiopathic venous thromboembolic events with documented LA and ACA results were included. The patients were divided into two groups based on the time between the acute VTE and initial APLA test. The frequency of abnormal LA and ACA on initial and repeat tests was determined in each group. 170 and 177 patients were screened for LA and ACA within one month of the acute VTE. On initial tests, LA and ACA were detected in 14.1% and 7.9% of patients, respectively. However, LA and ACA were present in only 1.2% and 1.7% of patients, respectively, on subsequent tests. In patients screened more than one month after an acute VTE 3.8% of the 52 patients had evidence of LA on initial testing and all were positive on repeat tests. ACA were present in 8% of patients on initial tests and in 6% (75% of the initial positive results) of patients on subsequent tests. A high frequency of positive LA and ACA tests results is observed when these tests are performed at the time of presentation of acute VTE. Repeat testing beyond one month from presentation demonstrates most of the results return to normal suggesting false positive results are common at presentation. However, when the tests are performed one month or longer after the acute VTE, the frequency of positive APLA test is much lower and false positives are uncommon. Screening for APLA should not be performed until at least one month after the diagnosis of idiopathic.

Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event

2009 ◽  
Vol 102 (12) ◽  
pp. 1219-1226 ◽  
Author(s):  
Paul Lukas ◽  
René Krummenacher ◽  
Franziska Biasiutti ◽  
Stefan Begré ◽  
Hansjörg Znoj ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Psychological Distress ◽  
Thromboembolic Event ◽  
Short Form ◽  
Depression Scale ◽  
Venous Thromboembolic Event ◽  
Anxiety And Depression ◽  
Blood Collection ◽  
Venous Thromboembolic

SummaryHealth-related quality of life (QoL) has been associated with several social and medical conditions in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE).To the best of our knowledge,there is no study investigating the relationship of QoL with psychological variables in this patient population.We assumed as a hypothesis an association between heightened levels of fatigue and psychological distress, as well as decreased QoL in patients with an objectively diagnosed venous thromboembolic event. Study participants were 205 consecutively enrolled out-patients (47.4 years, 54.6% men) with DVT and/or PE. Approximately 10 days before blood collection for thrombophilia work-up, QoL, fatigue, and psychological distress were assessed using the Short Form Health Survey (SF-12), the Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) as well as the Hospitality Anxiety and Depression scale (HADS). After controlling for demographic and medical factors, fatigue (p<0.01) but not psychological distress (p>0.05) was negatively associated with physical QoL, explaining 11.0% of the variance. Fatigue (p<0.001) and psychological distress (p<0.001) were significant predictors of mental QoL,explaining an additional 36.2% and 3.6% of the variance. Further analyses revealed that all subscales of the HADS (e.g. anxiety and depression) and of the MFSI-SF (e.g. general fatigue, physical fatigue, emotional fatigue, mental fatigue and vigor) were significant predictors of mental QoL. MFSI-SF subscales also predicted physical QoL. The findings suggest that fatigue and psychological distress substantially predict QoL in patients with a previous venous thromboembolic event above and beyond demographic factors.

scholarly journals Normal levels of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated

2010 ◽  
Vol 8 (1) ◽  
pp. 10 ◽  
Author(s):  
Leonard Minuk ◽  
Alejandro Lazo-Langner ◽  
Judy Kovacs ◽  
Melinda Robbins ◽  
Bev Morrow ◽  
...  
Keyword(s):  
Acute Phase ◽  
Protein C ◽  
Thromboembolic Event ◽  
Protein S ◽  
Venous Thromboembolic Event ◽  
Venous Thromboembolic

Relationship Between Psychological Distress and Endogenous Anticoagulants in Patients With a Previous Venous Thromboembolic Event

2010 ◽  
Vol 17 (2) ◽  
pp. 171-180 ◽  
Author(s):  
René Krummenacher ◽  
Paul S. Lukas ◽  
Franziska Demarmels Biasiutti ◽  
Stefan Begré ◽  
Hansjörg Znoj ◽  
...  
Keyword(s):  
Psychological Distress ◽  
Thromboembolic Event ◽  
Venous Thromboembolic Event ◽  
Venous Thromboembolic
Sign in / Sign up

Export Citation Format

Share Document